Suzhou Smart Nuclide Pharmaceutical Technology Company was founded in 2015, providing innovative diagnostic and therapeutic radiopharmaceuticals for patients around the world. Our products focus on thyroid cancer, precision radioactive imaging and targeted radioligand therapy. Since its foundation, Smart Nuclide has raised over 200 million yuan with four rounds of venture capital investment.
In Smart Nuclide, we build several technology platforms focusing on the discovery, R&D, and production of radiopharmaceuticals based on single-domain antibody, with independent intellectual property rights...
MoreR&D
We have set up four industry-leading platforms basing on the single domain antibody .
Investors
Partners
We are adhering to the concept of innovation and strengthening cooperation with universities, research institutes and hospitals , with a view to providing patients with the most innovative diagnostic and therapeutic products. At present, we have established cooperation with a number of institutions.
